First Patient Dosed in Phase 1 Trial of BT-001 for Rectal Cancer
Transgene and BioInvent reported the first patient has been dosed in the Phase 1 trial of BT-001 for rectal cancer.
Transgene and BioInvent reported the first patient has been dosed in the Phase 1 trial of BT-001 for rectal cancer.